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Background: Previous animal studies by us and others have indicated that catheter-administered plasmin or its
des-kringle derivatives may be more appropriate alternatives to plasminogen activators for treating thrombolytic
diseases, since it has a very short serum half-life and therefore does not result in hemorrhaging. We have previously
produced recombinant miniPlasmin (mPlasmin) that was proven suitable for treating peripheral arterial occlusion in
animal models. However, our previous results showed that non-specific cleavage at position K698 of mPlasmin
during activation hindered the further development of this promising therapeutic candidate. In order to minimize
or eliminate the non-specific cleavage problem, we performed saturation mutagenesis at the K698 position to
develop a mutant form of mPlasmin for thrombolytic therapy.
Methods: We changed K698 to 16 other amino acids, with preferred E. coli codons. Each of these mutants were
expressed in E. coli as inclusion bodies and then refolded, purified, and subsequently characterized by detailed
kinetic assays/experiments/studies which identified highly active mutants devoid of non-specific cleavage.
Results: Activation studies indicated that at those conditions in which the wild type enzyme is cut at the
non-specific position K698, the active mutants can be activated without being cleaved at this position.
Conclusions: From the above results, we selected two mutants, K698Q and K698N, as our lead candidates for
further thrombolytic drug developments. The selected mutants are potentially better therapeutic candidates for
thrombolytic therapy.
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The main goal of this study is to develop a better
thrombolytic therapeutic agent for thrombosis diseases,
such as deep vein thrombosis and peripheral arterial oc-
clusion (PAO). PAO occurs when a clot blocks artery
blood flow to a distant part of the body such as the legs,
arms, feet, or hands. PAO is the result of peripheral ar-
terial disease (PAD), in which atherosclerotic plaque
build-up on the artery walls leads to obstructed blood
flow, leading to ischemia in blood starved limbs of the
body [1].* Correspondence: shinlilin@yahoo.com
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reproduction in any medium, provided the orCurrent treatments of PAO include angioplasty, stents,
and thrombolytic intervention with ActivaseW (tissue-type
plasminogen activator, tPA) or AbbokinaseW (urokinase-
type plasminongen activator, uPA). Thrombolytic thera-
peutics are not currently approved by the FDA for PAO
because they require infusions that last a day or more and
are associated with high risk of serious bleeding including
stroke [2]. In humans, thrombolytic therapy with tPA
has been shown to cause potentially fatal intracranial
hemorrhage (ICH) in approximately 1% of patients re-
ceiving it for acute myocardial infarction [3]. The pa-
tient risk for ICH is even higher at 2.9% after prolonged
infusion treatment for PAO [4]. Thrombolytic interven-
tion against PAO has advanced concurrently with sig-
nificant technical advances in catheter design and
delivery, permitting local drug delivery directly into the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Preferred E. coli codons of the 16 amino acid
Amino acid Codon (E. coli) Amino acid Codon (E. coli)
Phe/F TTT Leu/L CTG
Tyr/Y TAT Pro/P CCG
Try/W TGG Gln/Q CAG
Ile/I ATC Val/V GTT
Ser/S AGC Ala/A GCG
Met/M ATG Asp/D GAT
Thr/T ACC Glu/E GAA
Asn/N AAC Gly/G GGT
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minogen activator (PA) mediated clot dissolution can be
slow, cumbersome, and only partially effective, requiring
1-2 days to take effect [4]. Furthermore, because the ef-
fectiveness of PAs is dependent on local plasminogen
(Plg) levels, Plg depletion problems occur due to long,
retracted clots and poor circulation. Consequently, this
renders PA therapy only partially effective for PAO, and
carries with it potential serious side effects [5]. There-
fore, alternative therapeutic options that are safer and
more efficient are desired. One such alternative strategy
is to directly use the activated form of Plg, Plasmin
(Plm), which digests fibrin in vivo. In practical consider-
ation, current advances in local drug delivery make Plm
or its des-kringle derivatives attractive for PAO treat-
ment. In particular, the issue of its very short serum
half-life has been addressed through catheter infusion
directly at the clot site as an alternative to IV adminis-
tration. At the same time, the very short half-life of Plm
offers the additional advantage of decreasing circulation
of the active enzyme to non-specific sites, thereby redu-
cing the risk of hemorrhaging and ICH.
As described above, breakdown of a fibrin clot (thrombi)
into soluble components depends on Plm, a serine prote-
ase that is derived from the freely circulating proenzyme
Plg [6]. Plg binds to both fibrin and fibrinogen, thereby
being incorporated into a clot as it is formed. In vivo, Plg
is activated by tPA trapped in the blood clot [7]. The
resulting Plm is transformed into two separate subunits
interconnected by 2 disulfide bridges. The A chain of the
Plm molecule consists of 5 triple-loop disulfide kringle
(Kr) domains (approximately 78-80 amino acids each),
while the B chain contains a “linker” region of 20 amino
acids and a serine protease domain (approximately 228
amino acids) [8]. Through laboratory manipulations, 2
des-kringle variants of Plg with potential pharmacological
application have been created. One of these, miniplasmi-
nogen (mPlg), consists of Kr5, the linker, and the serine
protease domain. The other, microplasminogen (μPlg),
consists of only the linker and serine protease domain it-
self. mPlg and μPlg are also activated to miniplasmin
(mPlm) and microplasmin (μPlm), respectively, by diges-
tion at the peptide bond between R561 and V562 (amino
acid number adapted from reference [8]). As in Plg, acti-
vation of mPlg and μPlg by tPA, uPA , or other PAs forms
two separate subunits interconnected by two disulfide
bridges.
In vitro studies have identified several interesting func-
tional differences between Plm, mPlm, and μPlm which
may have potential clinical significance in developing a
therapeutic drug. Functionally, μPlm is distinguished from
mPlm and Plm by its inability to specifically bind to fibrin;
μPlm lacks the fibrin binding resides in Kr1-Kr3 and
Kr5 domains [9-11]. While Plm and mPlm have similarcatalytic rates in digesting fibrin, μPlm is 6-fold slower
than mPlm and 12-fold slower than Plm [11]. Once fibrin
bound Plm dissociates from the blood clot, it becomes im-
mediately accessible to its principal inactivator, α2-anti-
plasmin (α2-AP). α2-AP first binds to specific lysine
residues located in Kr5 and other kringle domains before
binding to the catalytic domain, inactivating Plm for a
resulting plasma half-life of only 0.2 seconds [9,12,13].
Apart from the half-life issue, the desirability for pharma-
ceutical thrombolysis development is Plm>mPlm>μPlm
because of the fibrin binding specificity and the more
rapid kinetics in digesting fibrin [14].
During the preclinical drug development stage and ani-
mal testing, we observed that recombinant mPlm has bet-
ter pharmacological properties than μPlm, and decided to
develop mPlm as a thrombolytic therapeutic candidate.
However, during process development and scale up pro-
duction, we faced a non-specific cleavage problem during
activation of mPlg, hindering the development of this
promising drug candidate. In order to solve this problem,
we designed and screened mPlm mutants to select for
those that retain the desired catalytic properties, but have
much reduced tendency to be cleaved non-specifically.
Materials and methods
Materials
Wild type mPlg was purified in-house as described [15].
QuickChangeW Site-Directed Mutagenesis Kit used for site-
specific mutagenesis was from Stratagene. Chromogenic
substrate pGlu-Phe-Lys-pNA (S-2403) was from Chromo-
genix (Sweden). 4-Nitrophenyl 4-guanidinobenzoate hydro-
chloride (pNPGB) was from Aldrich. NUPAGE 4-12% BT
GEL was from Invitrogen. Other chemicals and protein
reagents such as fibrinogen and thrombin were from
SIGMA/Aldrich.
Mutagenesis design and method
For mutagenesis studies, we changed K698 to 16 other
amino acids, with preferred E. coli codons, as shown in
Table 1. This resulted in 16 mutant expression vectors.
A QuickChangeW Site-Directed Mutagenesis Kit with
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Each isolated mutant expression plasmid was sequence
verified, and expressed the same way as the wild-type
mPlg.
Inclusion body expression, purification, and refolding
screening
The sequence verified mutant plasmids were transformed
into E. coli strain BL21(DE3) for expression, refolding, and
purification following the same procedure as previously
described [15]. Briefly, E. coli containing the expression
plasmids were expressed in a high-density shaker flask
auto-induction system [16]. The broth was then spun
down and the pellet was washed extensively and put
through freeze thaw cycles with lysozyme to purify the in-
clusion bodies. The purified inclusion bodies were dis-
solved in an 8 M urea buffer (8 M urea, 0.1 M Tris, 1 mM
glycine, 1 mM EDTA, 10 mM β-mercaptoethanol, 10 mM
dithiothreitol (DTT), 1 mM reduced glutathione (GSH),
0.1 mM oxidized glutathione (GSSG), pH 10.5 with a final
concentration of 2 mg/ml). The solution was rapidly
diluted into 20 volumes of 20 mM Tris, 0.2 M L-arginine,
pH 10.5. The pH of the solution was slowly adjusted to
pH 8 with 6 M HCl as described [17]. The refolded pro-
tein was then concentrated by ultrafiltration, and purified
by various types of column chromatography as described
[15]. The expression level of each of the mutant mPlg was
essentially the same as that of the wild-type’s. For initial
screening, we grew 200 ml culture for wild-type mPlg and
each of the 16 mutants, yielding about 200 mg of highly
purified IB for each construct.
Activation and kinetic measurements
Kinetic measurement was performed similarly as described
[15]. Briefly, the kinetic parameters of the activated mPlg
wild-type and mutants were measured with a chromogenic
substrate pGlu-Phe-Lys-pNA (S-2403). The refolded and
purified zymogens (35.5 μM) were activated at 37°C for
10 min in a reaction mixture containing 25 mM Tris-HCl,
pH 7.4, 50 mM NaCl, and 0.37 μM of staphylokinase
(SAK). The active site of the activated mPlg was titrated
using pNPGB as described [18]. The activated zymogens
were diluted to 5.5 μM, and then 10 μl was mixed with
100 μl of 0.0625 mM, 0.125 mM, 0.25 mM, 0.5 mM,
0.75 mM, 1.0 mM, 1.5 mM, or 2.0 mM of substrate S-2403
in the assay buffer (25 mM Tris-HCl, 50 mM NaCl,
pH 7.4). The generation of amidolytic activity was moni-
tored (at 405 nm) at 37°C in 10 sec intervals for 20 min
using SpectraMax 250 microplate reader (Molecular
Devices). The data was plotted as velocity vs. substrate
using GraFit version 7 (Erithacus Software) and the Vmax
and Km of the wild-type and each mutant mPlm were
determined. The catalytic efficiency (Kcat/Km) was calcu-
lated according to the active enzyme concentration. Foraccessing the non-specific cleavage during activation, about
10 μg of wild-type and mutant mPlg were activated with
different concentrations of (around 0.03 μg) of SAK at vari-
ous temperature for different times, run on a 4-12% BT
gel, and stained with Coomassie Blue. For N-terminal se-
quencing of the cleaved bands, the activated wild type
mPlg and mutants were run on a 4-12% BT gel, transferred
to a PVDF membrane, and then stained with Coomassie
Blue. Desired bands were cut out from the membrane and
sent for N-terminal sequencing using Edman Degradation
at Iowa State University Protein Facility.
Fibrinolysis assay
A classical method was used for fibrinolytic assay [19,20].
Briefly, fibrin plates (9-cm BD Falcon Petri dish) were
made by combining fibrinogen (1.2 mg/ml final concen-
tration) and thrombin (0.3 NIH units/ml final concentra-
tion) in a 1.4% agarose solution. About 0.3-cm diameter/
0.22-cm height holes were punched after the agarose
plates solidified. Activated mPlg samples (15 μl) were
added to the holes to start the fibrinolysis reactions, after
which the plates were incubated at 37 for 5 and 10 hours.
At each time, the areas of the digest cycles were measured
and photograph were taken.
Staphylokinase (SAK) expression and purification
A synthetic SAK gene was constructed with optimized
E. coli codons according to protein sequence (accession
number: CAA24957 [21]). The synthetic gene was then
cloned into a T7 expression vector and the E. coli
expressed SAK was purified using ion exchange chroma-
tography. The activity of purified SAK was accessed
using the Plg activation method described above.
Results
We performed studies in a canine model which showed
our recombinant wild-type mPlm dissolved artificially
induced blood clots better than tPA (results not shown).
In a separate collaboration, a more detailed study of
mPlm in a canine artificial PAO model showed that
mPlm is better in reperfusion than tPA: while none of
the animals in mPlm group experienced reocclusion
after treatment, 20% of the tPA group reoccluded [22].
These results clearly demonstrate the effectiveness of
mPlm in treating PAO in the animal models.
During the scale up manufacturing process for mPlm
drug development, a problem of serious non-specific
cleavage of the mPlm was encountered during the ac-
tivation process using either uPA (Figure 1A) or SAK
(Figure 2A). After amino acid sequencing of the blotted
bands using N-terminal Edman degradation we found that
the major non-specific cleavage site is between K698 and
E699. A schematic presentation of the resulting fragments
is shown in Figure 1B. As shown in the 3-dimentional
Figure 1 Cleavage of mPlg activated by uPA. A. SDS-PAGE showing the products of purified mPlg (38.5 KD) after being activated using uPA.
The same results were obtained when SAK was used. Lane 1 is a molecular weight marker and Lane 2 is the activated mPlm. B. Diagram of
fragments R1, R2-1, R2-2, and R3. The left arrow shows the authentic activation cleavage between R561 and V562. This cleavage results in normal
activation fragments R1 (25.2 KD) and R2-1 (13.3 KD). The right arrow shows the non-specific cleavage between K698 and E699, which results in
extra-fragments of R2-2 (15.0 KD) and R3 (10.2 KD).
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R561 is at the activation loop. Cleavage at this site results
in normal activation fragments “R1” and “R2-1” shown in
Figure 1. The “R1” fragment was further cut at a non-
specific site between K698-E699, resulting in the “R3” and
“R2-2” fragments shown in Figure 1. The 3-D structure in
Figure 3A shows that K698 is located at the C-end of
the Autolysis Loop (the same position is Q in human
Trypsinogen and Bovine Chymotrypsin). Because trypsin-
like serine proteases have rather restricted requirements
for basic residues (R, K, H) at their P1 substrate position
[24], changing K698 residue to amino acids other than ar-
ginine and histidine should eliminate the non-specific
cleavage. Cysteine residue was also avoided in the muta-
genesis studies because of possible complications from
oxidation and incorrect disulfide bond formation during
refolding. Because of the difficulties inherent in calculating
a specific change that may result in better refolding, stabil-
ity, and activity, we decided to use a saturation mutagen-
esis strategy to change K698 to the rest of the 16 aminoacid residues, and to select the best mutant for further
drug development studies.
We constructed a mutant for each amino acid change
and cloned all 16 mutant expression vectors. The expres-
sion levels of all mutant mPlg in E. coli are similar to that
of the wild-type’s. The IBs were purified and refolded in
the same way as the wild-type. The refolded samples were
concentrated by ultrafiltration, and purified with Superdex
200 column chromatography (Figure 4), as described in
our previous publication [15]. In each SEC graph shown
in Figure 4, the first peak eluted from the void volume is
the non-folded soluble aggregates, and the latter peak
eluted, indicated by an arrow, is the folded, active protein.
The non-reduced SDS-PAGE of each column fraction in
the insert shows the first aggregation peak and the second
folded peak at the predicted molecular weight of the mPlg
monomer. As shown in Figure 4, all of the designed K698
mutants can be expressed, refolded, and purified with
similar characteristics as that of the wild-type mPlg. In
order to ensure that results are comparable and reliable,
Figure 2 Activation sites of wild-type and mutant mPlg. A. SDS-PAGE of wild-type and mutant mPlm activated with SAK. Standard molecular
weight is indicated on the right side. The number system for each mutant and the wild-type is labeled at the top, and is the same for Table 2. In
addition, mutations for each lane are labeled at the top of the figure with single amino acid letters. The two bands (15.0 and 10.2 KD) from the
major non-specific activation site at position K698 of the wild-type enzyme are highlighted at the left side of the figure. These two bands are not
present in mutant lanes. After activation at the R561 site (shown in C) for both wild-type and the mutants, two major bands (25.2 and 13.3 KD)
appear and are indicated with dots at the left side of the band. Molecular weights of other minor, non-specific cleavage bands are also labeled at
the left. B. Purified SAK (16 KD) used in this experiment. C. Schematic presentation of the cleavage sites derived from A. The activation site at
R561 is shown for both the wild-type and the mutants. The top scheme shows the cleavage pattern for the wild-type mPlm, which includes a
major non-specific cleavage site at K698, and two of the minor non-specific cleavage sites. The bottom scheme shows the cleavage pattern for
the mutants, in which the K698 position is no longer cleavable.
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the wild-type zymogen, and refolded them at the same
time. The purified and folded fractions were used for ac-
tivity tests and activation studies.
The main purpose of this study is to eliminate the
non-specific cleavage site at the K698 position. Figure 2A
shows the non-specific cleavage bands (15.0 and 10.2
KD) at Lane 2 of the wild-type enzyme. These two bands
are not present in any lanes of the mutants, indicating
that the non-specific cleavage at K698 was eliminated in
the mutants, validating the original goal of the design
(Figure 2A). The homogeneity of the SAK used in the
activation process is shown in Figure 2B, indicating that
SAK was highly purified. N-terminal amino acid se-
quencing of the cleavage fragments revealed other
minor non-specific cleavage sites under some experi-
mental conditions, which were designed to “over digest”
in order to clearly identify the non-specific cleavage
sites, corresponding to molecular weight 16.7, 8.5, and
4.8 kDa. Two of the minor cleavage sites, along with
the activation site and the K698 non-specific cleavage
site, are depicted in Figure 2C. The top of Figure 2Cdepicts the activation cleavage sites of the wild-type
mPlg: the activation site at R561, the major non-specific
cleavage site at K698, and two of the other minor non-
specific cleavage sites. The bottom of Figure 2C depicts
the activation cleavage sites of the mutant mPlg: the
same activation site at R561, and two of the other
minor cleavage sites under certain experimental condi-
tions. The K698 cleavage site, however, is completely
eliminated from all of the mutant mPlg studied.
The purified wild-type and mutant mPlg were acti-
vated with SAK, and kinetic parameters were measured
and compared as shown in Table 2. As expected, most
of the mutants have a lower refolding or catalytic effi-
ciency relative to wild-type. Of the 16 mutants, five have
higher refolding and catalytic efficiencies than other
mutants, although the Kcat/Km value are still lower than
the wild-type. These mutants, K698F, K698N, K698Q,
K698V, and K698M, along with the wild-type enzyme,
are highlighted with bold letters in Table 2. In particular,
the active mutants K698F, K698N, and K698Q have
significantly higher catalytic efficiency than the other
mutants.
Figure 3 Autolysis loop, K698 localization, and predicted phosphorylation sites in the structure of μPlg. The structure is viewed with
PyMOL software. The backbone is presented as a ribbon diagram and the Autolysis Loop is colored in red. Side chain colors follows: K698
(purple), R561 (purple), active side triad (H603, D646, S741) (cyan), and the predicted mammalian phosphorylation sites (yellow). The active site
serine (S741) was replaced with Alanine (A741) in the structure. A. Wild type μPlm. B. A model of K698Q mutant. The side chain for the Q residue
is in silver color.
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drolysis, in comparison with the wild-type enzyme
(Table 3). Although the table shows that the hydrolysis
rates of the two mutants (K698N, K698Q) are signifi-
cantly lower than that of the wild-type’s, further research
may prove the “druggability” of the selected mutants to-
ward thromboembolism related diseases, as will be dis-
cussed below.
Discussion
Our original interest in mPlm stemmed from results of
the animal studies cited above [25-27], experience in the
refolding of μPlg and mPlg, and structural interaction
with the PA streptokinase (SK) [23,28,29]. Reports in the
literature used 2.5-5.0 mg/kg μPlm to treat PAO in a
rabbit model [27], and similar amounts of mPlm in a
canine model [22]. Extrapolating to humans, an infusion
dose of as much as 200 mg would be required in a typ-
ical treatment (correcting for interspecies differences
between animals and humans). Because of the large
quantities of mPlm required for therapeutic efficacy,
using a mammalian, insect, or yeast (only ~3 mg/L, but
with no reports of functionality [30]) system to express
the protein for clinical development is not only cost-
prohibitive but also technically challenging. In contrast
to the monumental challenges involved in production
and expression in eukaryotic systems, expression in E.
coli is optimally suited for this task. However, mPlm can
only be over-expressed in the insoluble inclusion bodyform in E. coli (laboratory experience). We are able to
routinely obtain >1.2 g/L >80% pure mPlg in the form of
inclusion bodies from expression in shaker flasks. The
yield can potentially be much higher if an optimal pro-
cedure is established in a fermentation system. Thus ex-
pression in the inactive inclusion body form will be an
effective way to obtain large quantities of the protein for
thrombolytic drug development.
As described, despite success in mPlg refolding, purifi-
cation, and functional studies (including animal tests),
we encountered a serious non-specific cleavage problem
during activation using either uPA or SAK (Figure 1, 2).
We have also observed autoactivation problems during
long-term storage at 4°C [15], which is preventable in
our experience by controlling storage buffer composition
and storage temperature (frozen versus 4°C). On the
other hand, our results have shown that the non-specific
cleavage problem during activation could not be avoided
by controlling the activation conditions. We have tested
many different activation conditions including various
buffer conditions, different temperatures, and various
activation times but the non-specific cleavage problem
could not be eliminated. Non-specific cleavage during
activation decreases the specific activity of the purified
mPlm, rendering clinical development difficult if not im-
possible. As a first step towards solving this problem, we
identified the non-specific activation site by N-terminal
amino acid sequencing. Because Plg purified from
human serum can be activated to Plm without non-
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Purification of mutant mPlg using Superdex-200 SEC column. Results of wild type and all 16 mutants are shown. Each mutant was
expressed, refolded, and purified as described in the methods section. Non-reduced SDS-PAGE (4-12% polyacrylamide gradient gel) was used to
access the folding. Each batch of refolding was performed with the wild-type enzyme as a positive control. On the SDS-PAGE, the lower major
band in the second peak is the folded enzyme. In the SEC graph, the folded, active peak is indicated with red arrows.
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the non-specific cleavage at a specific site (K698) of the
recombinant mPlg. We postulate three possible mechan-
isms for the non-specific cleavage. The first mechanism
is that a certain percentage of the purified mPlg was not
refolded into the native conformation, but rather in an
inactive conformation that can easily be cleaved at pos-
ition K698. From our results shown in Table 2, under the
experimental condition described, when the wild-type
mPlg was activated without further purification, only
about 25% is in active form. The inactive form might be
in conformations such that the K698 position is readily
accessible for cleavage. The second possible mechanism
is that, under the activation conditions, the refolded pro-
tein may be in a “looser” conformation with respect to
the native conformation of the wild type enzyme, and
therefore may be more susceptible to non-specific cleav-
age. We have previously experienced similar situations
in which certain folded proteins are less stable than
those that are natively expressed. One of the main rea-






01_K698P 0.00375 11 ± 0.5 2145.3 ± 1
02_WT 0.1265 207 ± 4.9 347 ± 25
03_K698L 0.0685 126 ± 6.8 2459 ± 20
04_K698F 0.124 97 ± 4.6 439 ± 59
05_K698D 0.046 17 ± 1 587 ± 83
06_K698W 0.0065 72 ± 8 9686 ± 12
07_K698T 0.007 24 ± 1 4107 ± 22
08_K698N 0.1625 224 ± 4.4 811 ± 35
09_K698I 0.399 152 ± 6.6 1587 ± 11
10_K698Q 0.129 213 ± 6.5 1406 ± 76
11_K698E 0.1905 62 ± 2.8 2411 ± 16
12_K698V 0.154 202 ± 5.6 1609 ± 77
13_K698G 0.108 11 ± 1.4 617 ± 181
14_K698M 0.127 221 ± 5.6 1664 ± 71
15_K698Y 0.3545 33 ± 1.9 2451 ± 20
16_K698S 0.1405 39 ± 1.3 1776 ± 96
17_K698A 0.046 11 ± 0.7 885 ± 111
*Column 1 in Table 2 shows different mutants (WT: wild-type). Column 2 shows the
either refolding efficiency or stability of the active zymogen. The concentration of t
and calculated kinetic parameters; column 7 shows the ratio of the catalytic efficienin the post-translational modifications between mam-
malian and bacterial hosts. This leads us to the third
possible mechanism of non-specific cleavage, which is
the post-translational modification difference. The post-
translational modifications that may influence the stabil-
ity of mPlg include glycosylation, phosphorylation, and
sulfation. Using the ExPASy server (http://www.expasy.
org/), we identified no predicted glycosylation site in
mPlg. However, we have identified 18 mammalian phos-
phorylation sites in mPlg: 8 Ser sites, 4 Thr sites, and 6
Tyr sites. These sites are labeled in the 3-D structure of
μPlg (Figure 3), which clearly shows that almost all of
the predicted phosphorylation residues are located on
the surface of the protein (with the majority on surface
loops). Besides possible regulatory roles, phosphoryl-
ation may contribute to the solubility and stability of
the native protein. Although there are specific studies
for protein phosphorylation in E. coli [31], methods to
predict the specific phosphorylation of mammalian pro-
teins expressed in E. coli remain elusive. On the other




45.5 2933 1.37 0.29
1636 4.72 1
1 1839 0.75 0.16
782 1.78 0.38
370 0.63 0.13
22 11077 1.14 0.24
1 3429 0.83 0.18
1378 1.7 0.36
8 381 0.24 0.05
1651 1.17 0.25




9 93 0.04 0.01
278 0.16 0.03
239 0.27 0.06
active enzyme calculated from active site titration, which is an indication of
he active enzyme was used to calculate Kcat. Columns 3-7 show the measured
cy of different mutants compared with the wild-type, which is set to 1.






0.05 125.7 ± 4.2 126.7 ± 8.5 71.1 ± 10.6
0.1 194.9 ± 8.8 151.8 ± 9.3 100.8 ± 20.1
0.2 217.9 ± 16.6 189.9 ± 1.7 138.0 ± 13.2
0.4 279.1 ± 2.1 233.8 ± 9.6 182.9 ± 18.6
0.8 308.1 ± 22.0 268.8 ± 4.1 203.7 ± 10.7
*Area at each data point was calculated (A = πr2) by measuring the radius W of
the digestion ring.
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and this may contribute to the “loose” conformation of
the refolded mPlg under the activation conditions when
expressed in E. coli. For other modifications, there is
only one predicted sulfation site in mPlg (Y535), which
is located at the kringle region and is unlikely to influ-
ence the refolding and stability of the catalytic domain
of mPlg. For therapeutic drug development, using peg-
gylation may reduce the possible immunogenesis pro-
blems of the refolded protein, with possible trade off of
reduced activity.
We performed preliminary kinetic measurements of
the mutants as comparing with the wild-type mPlm, as
shown in Table 2. Since this is the first screening step
toward our ultimate goal of therapeutic drug develop-
ment, we did not optimize refolding and purification
conditions for the mutants. It is likely that each mutant
will require different optimized refolding and purifica-
tion conditions, and the conditions we optimized for the
wild-type may not be suitable for the mutants. Although
it is possible that some mutants are inherently less effi-
cient than the wild-type, we believe that the lack of
optimization may be the major reason that the catalytic
efficiency of the selected mutants (e.g. K698N and
K698Q) are significantly lower than the wild-type’s, as
shown in Table 2 and Table 3. As the next step of our
planned drug development program, we will be concen-
trated on optimize the refolding and purification condi-
tions for K698N and K698Q, and ultimately select one
mutant as our therapeutic drug candidate.
Conclusion
In this study, we used structure based mutagenesis and
screening methods to select protein therapeutics that are
more amendable for the drug manufacturing procedure
development. Figure 1 clearly shows K698 cleavage frag-
ments, and Figure 2 shows additional “minor” cleavage
sites at the R474 and R814 positions. The differences be-
tween these two results are procedural: in Figure 1, condi-
tions were controlled to achieve complete activation of
the wild-type enzyme without “overkill” to produce minorcleavage. The activated product was further purified be-
fore running the SDS-PAGE. In Figure 2, in order to ob-
serve the differences between the wild-type and mutants,
we over digested the zymogen and used crude digests to
run the SDS-PAGE. The minor cleavage sites shown in
Figure 2 were therefore unavoidable.
In addition, Table 2, column 2 shows an active site titra-
tion of the wild-type and mutant mPlm. The titration
shows that under the activation conditions, only about
25% of the wild-type mPlm is active, with some mutants
active and the rest in soluble, inactive forms. The inactive
proteins may have incorrectly folded conformations or
they may have lost activity because of over digestion.
Table 2 also shows that the active fractions of most of the
mutants are lower than the wild-type enzyme, with excep-
tions of K698I, K698Y, K698N, and K698E. The results
could be because most of the mutants are less stable than
the wild-type, but could also be due to the fact that the
refolding, purification, and activation conditions were not
optimized for each mutant under the experimental condi-
tions. Some of the mutants, such as K698P, K698W, and
K698T have approximately 50-fold lower active form and
10-fold higher Km values when compared to wild type,
indicating they are inactive mutants. These mutants are
difficult to refold and therefore are not suitable for drug
development. As shown in the Results section, K698F,
K698N, and K698Q have significantly higher catalytic effi-
ciency than the other mutants. In addition, the fibrinolytic
assay shows that although the catalytic efficiency of the
selected mutants is slightly lower, for practical applications
the efficacy can be compensated by applying higher
amounts of the selected mutants (Table 3). Modeling of
the 3-demensional structure shows that replacing K698
with glutamine (K698Q) results in minimal structural dis-
turbance (Figure 3B). The side-chain of K698Q has similar
length relative to the wild-type K698, and both have a sol-
uble terminal residue in which the only difference is the
charge at neutral pH in a water solution. Taking into ac-
count the data from Figure 2 and Table 2, as well as struc-
tural considerations shown in Figure 3B, we identified
K698N and K698Q as our lead candidate for further drug
development.
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